Clinical Scorecard: Transdermal NSAID Matches Oral Celecoxib After Knee Replacement
At a Glance
| Category | Detail |
|---|---|
| Condition | Post-operative pain control after total knee arthroplasty |
| Key Mechanisms | Transdermal esflurbiprofen patch vs. oral celecoxib for pain management |
| Target Population | Patients aged 50 years or older undergoing primary unilateral total knee arthroplasty for knee osteoarthritis |
| Care Setting | Single-center, prospective, randomized controlled trial |
Key Highlights
- Transdermal esflurbiprofen provided noninferior pain control compared to oral celecoxib.
- Both treatments resulted in similar pain scores and functional recovery at 6 weeks.
- No patients required rescue morphine in either treatment group.
- Safety outcomes were comparable, with no serious adverse events reported.
- Study limitations include small sample size and short treatment duration.
Guideline-Based Recommendations
Diagnosis
Management
- Consider transdermal esflurbiprofen as an alternative to oral celecoxib for post-operative pain control.
Monitoring & Follow-up
- Monitor kidney function at baseline, postoperative day 1, week 2, and week 6.
Risks
- Potential for unidentified rare side effects due to the study's limitations.
Patient & Prescribing Data
Patients aged 50 years or older undergoing total knee arthroplasty.
Both transdermal esflurbiprofen and oral celecoxib were effective in managing post-operative pain.
Clinical Best Practices
- Implement multimodal pain management regimens including paracetamol and pregabalin.
- Assess pain intensity using visual analog scale post-operatively.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
